Cassava Sciences, Inc. (SAVA)
After hours:
| Previous close | 34.14 |
| Open | 34.00 |
| Bid | 35.36 x 1100 |
| Ask | 35.74 x 1000 |
| Day's range | 33.73 - 36.47 |
| 52-week range | 13.84 - 62.49 |
| Volume | |
| Avg. volume | 2,409,714 |
| Market cap | 1.495B |
| Beta (5Y monthly) | 0.08 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 13 Dec 2012 |
| 1y target est | N/A |
- GlobeNewswire
Cassava Sciences Announces Closing of $50 Million Registered Direct Offering
AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 1,666,667 shares of its common stock, at a purchase price per share of $30, for gross proceeds of approximately $50 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. JonesTrading
- GlobeNewswire
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has entered into a definitive agreement with several healthcare-focused and other institutional investors for the purchase of 1,666,667 shares of its common stock, at a purchase price of $30 per share, for gross proceeds of approximately $50 million, in a registered direct offer
- GlobeNewswire
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
– $174.7 Million Cash and Cash Equivalents at September 30, 2022 – – Over 650 Patients Now Enrolled in Phase 3 Program - – New Clinical Data for Simufilam in Alzheimer’s Disease Expected – AUSTIN, Texas, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the third quarter ended September 30, 2022 and provided a clinical update on its Phase 3 clinical program of simuf
